Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838993 | 1.00 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GUSP30SYK | |
| Ammonia Solution, Strong SCHEMBL4156140 | 0.99 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GUSP30SYK | |
| Ammonia Solution, Strong SCHEMBL4156138 | 0.99 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GUSP30SYK | |
| SCHEMBL4155399 | 0.92 | KDM4E (0.38) | USP30SYKKDM4EALDH1A1TP53 | |
| SCHEMBL4155397 | 0.92 | KDM4E (0.38) | USP30SYKKDM4EALDH1A1TP53 | |
| SCHEMBL4140094 | 0.92 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GSYKNR1I2 | |
| SCHEMBL4140087 | 0.92 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GSYKNR1I2 | |
| SCHEMBL4823092 | 0.91 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GSYKNR1I2 | |
| SCHEMBL4789893 | 0.91 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GSYKNR1I2 | |
| SCHEMBL4789894 | 0.91 | CYP2E1 (0.36) | CYP2E1APOBEC3AAPOBEC3GSYKNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | CYP2E1 207/4885APOBEC3A 938/4885APOBEC3G 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.